image description

Tag: Aurinia Pharmaceuticals

Lupus Research Alliance Hails Approval of Aurinia’s Lupkynis(TM) (voclosoporin)

First Oral Treatment for Lupus Nephritis; Second Lupus Treatment to Receive FDA Approval in Past Month NEW YORK, NY. January 22, 2021. The Lupus Research Alliance (LRA) is excited to share that the U.S. Food and Drug Administration (FDA) approved the use of Aurinia Pharmaceuticals’ LupkynisTM (voclosporin) as the first oral treatment developed specifically for […] Read More

Data Shows Voclosporin Preserves Kidney Function for Three Years

July 19,2023 The LRA is pleased to share news announced by Aurinia Pharmaceuticals of published results showing that the lupus treatment, voclosporin (Lupkynis) preserved kidney function up to three years among lupus nephritis.  These results of the Phase 3, double-blind, placebo-controlled AURORA 2 extension study were published in the official peer-reviewed professional journal of the […] Read More

Aurinia Announces Positive Long-Term Results on Lupykinis™ for Lupus Nephritis

December 9, 2021 The LRA is pleased to share positive topline three-year efficacy and safety results reported today by Aurinia Pharmaceuticals from the AURORA 2 continuation study of Lupkynis™ (voclosporin). These results provide the longest available data for an FDA-approved medicine in lupus nephritis. The U.S. Food and Drug Administration approved Lupkynis arlier this year […] Read More

LRA Congratulates Aurinia on Published Results with FDA-Approved Lupkynis™

May 10, 2021 The highly prestigious medical journal The Lancet published the results of Aurinia’s Phase 3 AURORA 1 study testing Lupkynis™ (voclosporin) in adults with lupus nephritis. Lupkynis was approved by the U.S. Food and Drug Administration based on these data. The AURORA 1 study results showed that Lupkynis in combination with the commonly used […] Read More
Stay informed about events, research developments, and ways you can help. Sign up for updates